Contrast-Enhanced Mammography for Breast Abnormalities

Overseen By Suzanne Burdin, BS

Age: 18+

Sex: Female

Trial Phase: Phase 4

Sponsor: Margarita Louise Zuley

Disqualifiers: Breast implants, Pregnancy, Breast-feeding, Cancer treatment, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 4 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 1

2100 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new type of mammogram, called contrast-enhanced mammography (CEM), which might reduce the need for unnecessary biopsies in women with certain suspicious breast findings. The goal is to determine if CEM can accurately identify non-cancerous breast abnormalities, thereby reducing stress and anxiety for patients. Women diagnosed with a suspicious breast abnormality and scheduled for a biopsy might be suitable candidates for this trial. As a Phase 4 trial, this research aims to understand how this FDA-approved and effective treatment can benefit more patients.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. However, if you are actively being treated for cancer with chemotherapy, you cannot participate in the trial.

What is the safety track record for Contrast Enhanced Mammography and Iodinated Contrast Media?

Research shows that contrast-enhanced mammography (CEM) is generally safe. Studies have found that CEM can help doctors more accurately identify breast problems, potentially determining if something is cancerous without extra, stressful tests.

The FDA has approved CEM for examining breast cancer in women already diagnosed, indicating that the procedure is well-tolerated. Most people do not experience serious side effects, though there are some risks. These might include mild reactions to the contrast dye, such as feeling warm or having a slight allergic reaction.

Overall, CEM is considered a helpful and safe tool in breast imaging. Discussing any concerns with a healthcare provider can help in making the best decision for one's health. ^{1 2 3 4 5}

Why are researchers enthusiastic about this study treatment?

Contrast-enhanced mammography is unique because it offers a more detailed and precise imaging technique compared to traditional mammography. Unlike standard mammograms that use X-rays alone, this method involves injecting a contrast dye that highlights blood vessels, potentially improving the detection of suspicious breast abnormalities. Researchers are excited about this technique because it could lead to more accurate diagnoses, reducing the need for unnecessary biopsies and providing clearer guidance for treatment decisions.

What evidence suggests that contrast-enhanced mammography is effective for reducing unnecessary biopsies in breast abnormalities?

Research has shown that contrast-enhanced mammography (CEM), which participants in this trial will undergo, improves the accuracy of breast cancer detection. Studies have found CEM particularly useful when regular breast imaging results are unclear. For example, CEM can detect cancer earlier in women with dense breast tissue without increasing false alarms. This leads to fewer unnecessary biopsies and less anxiety for patients about non-cancerous results. Additionally, if CEM indicates no cancer, there is a very high likelihood that the person is indeed cancer-free. ^{1 3 4 6 7}

Who Is on the Research Team?

Margarita L Zuley, MD

Principal Investigator

University of Pittsburgh

Are You a Good Fit for This Trial?

This trial is for women aged 30 or older with suspicious breast abnormalities scheduled for a biopsy. It's not suitable for pregnant or breastfeeding women, those on chemotherapy, with reduced kidney function (eGFR < 45), known allergies to iodinated contrast, or who have a breast implant in the affected breast.

Inclusion Criteria

I am a woman.

I am scheduled for a biopsy due to a suspicious finding in my breast.

I am 30 years old or older.

Exclusion Criteria

Subject has had a prior reaction to iodinated contrast; thus a known allergy to iodinated contrast

I am currently receiving chemotherapy for cancer.

You have a breast implant in the breast being studied.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Diagnostic Evaluation

Participants undergo contrast enhanced mammography (CEM) to assess breast abnormalities before scheduled biopsy

1 week

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness of CEM in reducing biopsy recommendations

5 years

What Are the Treatments Tested in This Trial?

Interventions

• Contrast Enhanced Mammography
• Iodinated Contrast Media (ICM)

Trial Overview

The study tests if Contrast-Enhanced Mammography (CEM) using Iodinated Contrast Media can reduce unnecessary biopsies in cases rated BI-RADS 4A/4B while maintaining high cancer detection rates. Participants will undergo CEM before their planned biopsy to evaluate its effectiveness.

How Is the Trial Designed?

Group I: contrast enhanced mammography Experimental Treatment 2 Interventions

Women who have been recently diagnosed with a suspicious abnormality for which they have scheduled a breast biopsy and meet inclusion criteria will be invited to have a contrast enhanced mammography before their scheduled biopsy procedure.

Contrast Enhanced Mammography is already approved in European Union, United States, Canada for the following indications:

Approved in European Union as Contrast-Enhanced Mammography for:

• Breast cancer screening
• Evaluation of breast abnormalities
• Preoperative staging of breast cancer
• Monitoring response to neoadjuvant chemotherapy

Approved in United States as Contrast-Enhanced Mammography for:

• Breast cancer screening
• Evaluation of breast abnormalities
• Preoperative staging of breast cancer
• Monitoring response to neoadjuvant chemotherapy

Approved in Canada as Contrast-Enhanced Mammography for:

• Breast cancer screening
• Evaluation of breast abnormalities
• Preoperative staging of breast cancer
• Monitoring response to neoadjuvant chemotherapy

Who Is Running the Clinical Trial?

Margarita Louise Zuley

Lead Sponsor

Trials

1

Recruited

1,900+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Published Research Related to This Trial

Dual-energy contrast-enhanced mammography (CESM) is a promising new imaging technique for breast cancer that aims to overcome the limitations of traditional methods like MRI and CT, which can be expensive and expose patients to high radiation doses.

The review highlights both the advantages of CESM, such as improved imaging capabilities, and its drawbacks, indicating a need for further research to optimize its use in breast care.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Dual-energy contrast-enhanced spectral mammography (CESM). Daniaux, M., De Zordo, T., Santner, W., et al.[2018]

In a study analyzing 152 breast lesions (44 benign and 108 malignant) using contrast-enhanced spectral mammography (CESM), malignant lesions showed significantly stronger enhancement compared to benign ones, indicating CESM's potential for effective differentiation between lesion types.

The study found that CESM could accurately classify lesions with a sensitivity of 75.9% and specificity of 88.6%, suggesting it is a reliable tool for assessing breast lesions based on their enhancement patterns.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Quantitative analysis of enhanced malignant and benign lesions on contrast-enhanced spectral mammography. Deng, CY., Juan, YH., Cheung, YC., et al.[2019]

Contrast-enhanced spectral mammography (CESM) results in a significant increase in radiation dose compared to full-field digital mammography (FFDM), with an average glandular dose (AGD) increase of 1.25 mGy (+81%) and entrance skin air kerma (ESAK) increase of 3.07 mGy (+41%).

Despite the increased radiation exposure with CESM, both CESM and FFDM doses remain within the recommended safety limits for mammography, indicating that while CESM is more intense, it is still considered safe for patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Radiation exposure of contrast-enhanced spectral mammography compared with full-field digital mammography. Jeukens, CR., Lalji, UC., Meijer, E., et al.[2015]

The dual-energy contrast agent-enhanced digital subtraction mammography technique was tested on 26 subjects and successfully identified 13 cases of invasive breast cancer, demonstrating its potential efficacy in cancer detection.

The technique showed varying levels of enhancement in tumors, with most invasive cancers exhibiting strong enhancement, suggesting that it could improve the visualization of breast cancers compared to traditional methods.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Dual-energy contrast-enhanced digital subtraction mammography: feasibility. Lewin, JM., Isaacs, PK., Vance, V., et al.[2022]

In a study of 44 women with unclear mammogram results, contrast-enhanced dual-energy spectral mammogram (CEDM) identified 20% of lesions that were not visible on standard mammograms, highlighting its effectiveness in detecting hidden issues, especially in dense breast tissue.

CEDM not only helped in confirming the presence of lesions but also provided detailed information about their extent and characteristics, making it a valuable tool for triaging and managing breast lesions alongside traditional mammography.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Contrast enhanced dual energy spectral mammogram, an emerging addendum in breast imaging. Kariyappa, KD., Gnanaprakasam, F., Anand, S., et al.[2018]

Dual-energy contrast-enhanced mammography is a promising new imaging technique that provides insights into the vascularization of breast lesions, which is linked to their malignancy.

Based on 15 months of clinical experience, this technique offers additional information beyond traditional mammography, helping to improve the assessment of breast lesions, although it also has its limitations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Dual-energy contrast-enhanced mammography. Travieso Aja, MM., Rodríguez Rodríguez, M., Alayón Hernández, S., et al.[2016]

Contrast-enhanced spectral mammography (CESM) demonstrated significantly higher sensitivity (86.2%) and specificity (94.1%) compared to conventional digital mammography (MMG), which had a sensitivity of only 53.4% and specificity of 85.9%, based on a study of 143 breasts from 72 women.

CESM was particularly effective in detecting breast cancer in dense breasts, identifying 80% of malignancies that MMG missed, suggesting that CESM could reduce false negatives in this high-risk group.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Diagnostic accuracy of contrast-enhanced spectral mammography in comparison to conventional full-field digital mammography in a population of women with dense breasts. Mori, M., Akashi-Tanaka, S., Suzuki, S., et al.[2019]

Contrast-enhanced spectral mammography (CESM) significantly improves diagnostic accuracy compared to conventional mammography, achieving 100% sensitivity and 87.7% specificity in a study of 113 women referred from a breast cancer screening program.

CESM not only outperforms mammography in detecting breast cancer but also shows comparable results to MRI and histopathology in assessing the extent of cancer, making it a valuable tool even in populations with lower disease prevalence.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Contrast-enhanced spectral mammography in patients referred from the breast cancer screening programme. Lobbes, MB., Lalji, U., Houwers, J., et al.[2022]

A systematic review of 84 studies involving 14,012 patients found that contrast-enhanced spectral mammography (CESM) is generally safe, with a low adverse reaction rate of 0.82%, including only one severe non-fatal reaction.

The study highlighted the need for standardization in CESM protocols, as most studies used similar parameters, such as a contrast dose of 1.5 mL/kg at a flow rate of 3 mL/s and a 120-second acquisition delay, but only half of the studies were prospective.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Technique, protocols and adverse reactions for contrast-enhanced spectral mammography (CESM): a systematic review. Zanardo, M., Cozzi, A., Trimboli, RM., et al.[2020]

Dual-energy contrast-enhanced spectral mammography (DE-CESM) effectively enhances the diagnosis of suspicious malignant microcalcifications, showing a high diagnostic sensitivity of 90.9% and specificity of 83.78% based on a study of 59 cases with pathological diagnoses.

The method also provides accurate measurements of cancer size, with a mean difference of only 0.05 cm compared to surgical histology, indicating its reliability for evaluating breast cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical utility of dual-energy contrast-enhanced spectral mammography for breast microcalcifications without associated mass: a preliminary analysis. Cheung, YC., Tsai, HP., Lo, YF., et al.[2020]

Contrast-enhanced spectral mammography (CESM) significantly improves the accuracy of breast cancer detection by reducing false-positive and false-negative results while maintaining high sensitivity.

The study highlights that many artifacts affecting image quality in CESM can be easily resolved, providing valuable insights for practitioners to enhance the effectiveness of this imaging technique.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Contrast-enhanced Spectral Mammography: Modality-Specific Artifacts and Other Factors Which May Interfere with Image Quality. Bhimani, C., Li, L., Liao, L., et al.[2018]

Dual-energy contrast-enhanced spectral mammography (CESM) significantly improves the diagnosis of breast cancer in dense breasts, increasing sensitivity from 71.5% to 92.7% and accuracy from 65.9% to 85.8% compared to conventional mammography.

CESM also enhances interobserver consistency among radiologists, indicating that it provides more reliable diagnostic information regardless of the reader's experience level.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Diagnostic performance of dual-energy contrast-enhanced subtracted mammography in dense breasts compared to mammography alone: interobserver blind-reading analysis. Cheung, YC., Lin, YC., Wan, YL., et al.[2022]

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC11674923/

Contrast-Enhanced Mammography: A Literature Review of ...

Contrast-enhanced mammography is a modern mammographic examination simultaneously using low- and high-energy exposures after the administration ...

2.

pubs.rsna.org

pubs.rsna.org/doi/full/10.1148/radiol.2021201948

Contrast-enhanced Mammography: State of the Art

Contrast-enhanced mammography is an emerging breast imaging modality that helps improve diagnostic accuracy when routine breast imaging produces inconclusive ...

3.

sciencedirect.com

sciencedirect.com/science/article/pii/S0720048X25004371

Contrast-Enhanced Mammography: Bridging the research ...

Interim results have demonstrated that supplemental contrast imaging facilitate earlier cancer detection in women with dense breasts, without significant ...

4.

ajronline.org

ajronline.org/doi/10.2214/AJR.17.19265

Contrast-Enhanced Mammography: A Systematic Guide to ...

This article is to discuss the essential steps involved in performing, interpreting, managing, and reporting findings on contrast-enhanced mammography.

5.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC8018270/

The effectiveness of contrast-enhanced spectral ...

Among them, the 2 latest techniques are based on mammography: contrast-enhanced spectral mammography (CESM) and digital breast tomosynthesis (DBT). Magnetic ...

6.

densebreast-info.org

densebreast-info.org/screening-technologies/contrast-enhanced-mammography/

Contrast-Enhanced Mammography (CEM) | DenseBreast ...

CEM is FDA-approved for diagnostic breast imaging, and is proven effective in looking at the extent of cancer in women with newly diagnosed ...

7.

clinicaltrials.gov

clinicaltrials.gov/study/NCT05625659

Comparison of Breast Cancer Screening With CESM to ...

Comparison of Breast Cancer Screening With Dual-Energy Contrast-Enhanced Spectral Mammography to Digital Breast Tomosynthesis in Women With Dense Breasts ...